These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 17672075)

  • 21. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
    Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
    Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.
    Redman AR; Zheng J; Shamsi SA; Huo J; Kelly EJ; Ho RJ; Ritchie DM; Hon YY
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):29-37. PubMed ID: 17895500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
    Caraco Y; Blotnick S; Muszkat M
    Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
    Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
    N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
    Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
    Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Khasanova ZB; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(12):43-8. PubMed ID: 22416444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial.
    Colli A; Mestres CA; Castella M; Gherli T
    J Heart Valve Dis; 2007 Nov; 16(6):667-71. PubMed ID: 18095518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
    Samardzija M; Topić E; Stefanović M; Zibar L; Samardzija G; Balen S; Vcev A; Domanović D; Mirat J; Barbić J
    Coll Antropol; 2008 Jun; 32(2):557-64. PubMed ID: 18756910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
    Girón-González JA; García del Río E; Rodríguez C; Rodríguez-Martorell J; Serrano A
    J Rheumatol; 2004 Aug; 31(8):1560-7. PubMed ID: 15290736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
    Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D
    Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
    Ames PR; Margaglione M; Ciampa A; Colaizzo D; Ferrara F; Iannaccone L; Vincenzobrancaccio
    Thromb Res; 2011 Jun; 127(6):595-9. PubMed ID: 21371740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current management of antiphospholipid syndrome-related thrombosis.
    Puente D; Pombo G; Forastiero R
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1551-8. PubMed ID: 19954317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.